Colleen F. Reitan, Director at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 34,323 shares at $477.47 ($16.1M) on 2025-09-09, disclosed to the SEC on 2025-09-11.
Scheduled sale ($16.1M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $457.44 | 1,645 | $752K | 4.7% |
| 2 | $457.44 | 1,645 | $752K | 4.7% |
| 3 | $458.86 | 1,888 | $866K | 5.4% |
| 4 | $458.86 | 1,888 | $866K | 5.4% |
| 5 | $459.73 | 1,403 | $645K | 4.0% |
| 6 | $459.73 | 1,403 |
| $645K |
| 4.0% |
| 7 | $460.71 | 473 | $218K | 1.4% |
| 8 | $460.71 | 473 | $218K | 1.4% |
| 9 | $461.92 | 2,290 | $1.1M | 6.6% |
| 10 | $461.92 | 2,290 | $1.1M | 6.6% |
| 11 | $463.00 | 1,652 | $765K | 4.8% |
| 12 | $464.36 | 799 | $371K | 2.3% |
| 13 | $464.36 | 799 | $371K | 2.3% |
| 14 | $471.25 | 222 | $105K | 0.7% |
| 15 | $471.25 | 222 | $105K | 0.7% |
| 16 | $472.82 | 823 | $389K | 2.4% |
| 17 | $472.82 | 823 | $389K | 2.4% |
| 18 | $474.22 | 838 | $397K | 2.5% |
| 19 | $474.22 | 838 | $397K | 2.5% |
| 20 | $474.85 | 951 | $452K | 2.8% |
| 21 | $474.85 | 951 | $452K | 2.8% |
| 22 | $476.31 | 972 | $463K | 2.9% |
| 23 | $476.31 | 972 | $463K | 2.9% |
| 24 | $477.47 | 1,183 | $565K | 3.5% |
| 25 | $477.47 | 1,183 | $565K | 3.5% |
| 26 | $478.67 | 1,450 | $694K | 4.3% |
| 27 | $478.67 | 1,450 | $694K | 4.3% |
| 28 | $479.55 | 1,386 | $665K | 4.1% |
| 29 | $479.55 | 1,386 | $665K | 4.1% |
| 30 | $480.98 | 25 | $12K | 0.1% |
| Total | $467.81 avg | 34,323 | $16.1M | 100% |
| Filing → |
| MYGN | SELL | 2024-09-04 | $2.6M | — | Filing → |